We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+2.79%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$24.1M
Cap. Flow
+$28.6M
Cap. Flow %
18.87%
Top 10 Hldgs %
90.44%
Holding
21
New
3
Increased
4
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.7M
2
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$10.7M
3
HOOK
HOOKIPA Pharma
HOOK
+$5.62M
4
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$4.64M
5
RGLS
Regulus Therapeutics
RGLS
+$1.04M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$2.99M
2
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.81M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$26.3M 17.38%
330,697
+119,760
+57% +$10.7M
ODT
2
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$22.6M 14.93%
615,850
+20,000
+3% +$479K
ALLK
3
DELISTED
Allakos
ALLK
$18.9M 12.47%
446,905
– –
SYRS
4
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15.2M 10.06%
172,660
+66,666
+63% +$4.64M
STRO icon
5
Sutro Biopharma
STRO
$379M
$12.8M 8.46%
112,558
– –
PRNB
6
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$12.7M 8.41%
383,480
– –
BCEL
7
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$11.1M 7.36%
+591,368
New +$10.7M
GOSS icon
8
Gossamer Bio
GOSS
$66.5M
$8.35M 5.52%
376,583
-156,337
-29% -$2.99M
LQDA icon
9
Liquidia Corp
LQDA
$7.67B
$5.27M 3.48%
658,532
+19,242
+3% +$181K
HOOK
10
DELISTED
HOOKIPA Pharma
HOOK
$3.57M 2.36%
+53,025
New +$5.62M
ARAV
11
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.66M 1.75%
442,733
– –
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
$2.63M 1.73%
118,500
– –
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$2.42M 1.6%
50,000
– –
EVLO
14
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$2.04M 1.35%
11,376
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.53M 1.01%
60,312
-46,831
-44% -$1.81M
UROV
16
DELISTED
Urovant Sciences Ltd.
UROV
$1.25M 0.82%
157,480
– –
RGLS
17
DELISTED
Regulus Therapeutics
RGLS
$1.13M 0.75%
+90,441
New +$1.04M
TPST icon
18
Tempest Therapeutics
TPST
$14.8M
$521K 0.34%
231
– –
SURF
19
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$221K 0.15%
78,300
– –
PDSB icon
20
PDS Biotechnology
PDSB
$38.1M
$55K 0.04%
9,166
– –
TRIL
21
DELISTED
Trillium Therapeutics Inc.
TRIL
$24K 0.02%
71,619
– –

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q2 2019 Portfolio in Review

As of Q2 2019, Samsara BioCapital held 21 positions worth $151M, up 19% from $127M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Samsara BioCapital deployed $28.6M of net new capital in Q2 2019, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Atreca, Inc. Class A Common Stock: 591,368 shares worth $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Gossamer Bio, an estimated $2.99M trimmed.

  • Samsara BioCapital's largest Q2 2019 buy was Atreca, Inc. Class A Common Stock: 591,368 shares worth $11.1M.
  • Samsara BioCapital added most to Intercept Pharmaceuticals, Inc. in Q2 2019, an estimated $10.7M increase.
  • Samsara BioCapital's biggest Q2 2019 reduction was Gossamer Bio, cutting an estimated $2.99M.
  • Samsara BioCapital's ten largest holdings make up 90% of its $151M portfolio in Q2 2019.
  • Samsara BioCapital opened 3 new positions and closed 0 in Q2 2019.
  • Samsara BioCapital's portfolio value rose 19% quarter-over-quarter to $151M.

Based on Samsara BioCapital's 13F filing for Q2 2019, filed 14 Aug 2019.